All In Biotech

NDA 021748 · Santarus INC

Glumetza

Metformin Hydrochloride · Oral

Discontinued

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 3, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,828

753 Phase 3, 150 recruiting

FAERS reports

60,186

43,694 serious, 5,792 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions ( 5.1 )] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Sep 2, 2026.

GLUMETZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUMETZA is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)

Mechanism: Metformin is a biguanide that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 3, 2005 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
2 products under this application
  • GLUMETZA · METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB3
  • GLUMETZA · METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.

All 2,828 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • lactic acidosis4,572
  • diarrhoea4,532
  • nausea3,677
  • acute kidney injury3,336
  • fatigue3,257
  • drug ineffective2,883
  • vomiting2,741
  • dyspnoea2,732
  • headache2,423
  • off label use2,267
  • dizziness2,240
  • asthenia2,181

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200494
2005133
2006408
2007284
2008441
2009676
2010984
2011950
20121,968
2013896
2014967
20151,954
20162,273
20172,672
20183,943
20193,228
20202,817
20213,533
20226,432
20236,369
20246,922
20257,079
20265,161

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Glumetza (Metformin HCl)

2024 spending

$19.8M

Beneficiaries

1,014

3,112 claims

Per beneficiary

$19,533

$73.01 per unit

View as table
YearSpending
2020$44,928,543
2021$44,842,796
2022$39,094,409
2023$37,772,978
2024$19,806,298

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,495 on PubMed

Sponsor: Santarus INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.